|Bid||1.1800 x 800|
|Ask||1.1900 x 29200|
|Day's Range||1.1800 - 1.1850|
|52 Week Range||0.8800 - 1.4200|
|Beta (3Y Monthly)||0.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.20|
The following is our latest Fund Analyst Report for American Century Value Inv TWVLX . Morningstar Premium Members have access to full analyst reports such as this for more than 1,000 of the largest and best mutual funds. American Century Value's seasoned manager still employs a solid approach, but recent struggles, analyst turnover, and a hefty price tag lead to a Morningstar Analyst downgrade to Bronze from Silver. Lead manager Michael Liss adds a contrarian bent to American Century's proven quality-driven process.
SAN JOSE, Calif. , Aug. 8, 2019 /PRNewswire/ -- Intermolecular, Inc. (Nasdaq: IMI), the trusted partner for advanced materials innovation, today reported results for its second quarter ended June 30, 2019 ...
SAN JOSE, Calif. , Aug. 1, 2019 /PRNewswire/ -- Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials innovation, today announced Intermolecular Senior Vice President of Programs ...
SAN JOSE, Calif., July 17, 2019 /PRNewswire/ -- Intermolecular, Inc. (IMI) announced today that the stockholders of Intermolecular have approved the previously announced proposed acquisition of all outstanding shares of common stock of Intermolecular by Merck KGaA, Darmstadt, Germany, through its subsidiary EMD Group Holding II, Inc. At a special meeting held earlier today, the holders of approximately 72% of Intermolecular's outstanding common stock voted in favor of the proposed merger transaction. The transaction is expected to close in the second half of 2019, subject to the satisfaction or waiver of customary closing conditions.
KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (firstname.lastname@example.org) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-imi/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of Intermolecular, Inc. (“Intermolecular”) (NASDAQ GS: IMI) common stock in connection with the proposed acquisition of Intermolecular by affiliates Merck KGaA (the “Buyers”) announced on May 6, 2019 (the “Complaint”). The Complaint, which alleges violations of the Securities Exchange Act of 1934 against Intermolecular and its Board of Directors (the “Board”), is captioned Franchi v. Intermolecular, Inc., Case No. 1:19-cv-01054 (D. Del.). On May 6, 2019, Intermolecular entered into an agreement and plan of merger (the “Merger Agreement”) with the Buyers. Pursuant to the terms of the Merger Agreement, shareholders of Intermolecular will receive $1.20 per share in cash (the “Proposed Transaction”).
NEW YORK, NY / ACCESSWIRE / June 24, 2019 / Halper Sadeh LLP, a global investor rights law firm, announces the filing of shareholder class action lawsuits against Intermolecular, Inc. (NASDAQ: IMI) and ...
NEW YORK, June 17, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Intermolecular, Inc.,.
NEW YORK, June 06, 2019 -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating Zayo Group Holdings, Inc. (NYSE: ZAYO), Chesapeake Lodging Trust.
NEW YORK , May 15, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Intermolecular, Inc. ("Intermolecular" ...
NEW YORK , May 15, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
On a per-share basis, the San Jose, California-based company said it had a loss of 5 cents. Losses, adjusted for stock option expense, were 4 cents per share. The materials research company semiconductor ...
SAN JOSE, Calif. , May 14, 2019 /PRNewswire/ -- Intermolecular, Inc. (Nasdaq: IMI), the trusted partner for advanced materials innovation, today reported results for its first quarter ended March 31, ...
NEW YORK, May 14, 2019 -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating Global Brass and Copper Holdings, Inc. (NYSE: BRSS), Gardner Denver.
NEW YORK , May 13, 2019 /PRNewswire/ -- 3M Company (MMM) Lifshitz & Miller announces investigation into possible securities laws violations in connection with 3M's reported financial and operating results ...
BALA CYNWYD, PA / ACCESSWIRE / May 6, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Intermolecular Inc ("Intermolecular" ...
NEW YORK, May 06, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Intermolecular, Inc. (NASDAQ: IMI) on behalf of.
WILMINGTON, Del., May 06, 2019 -- Rigrodsky & Long, P.A.: Do you own shares of Intermolecular, Inc. (NASDAQ GS: IMI)? Did you purchase any of your shares prior to May 6,.
NEW YORK, May 06, 2019 -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating Chesapeake Lodging Trust (NYSE: CHSP) and Intermolecular,.
NEW YORK, May 06, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Intermolecular, Inc..
SAN JOSE, Calif., May 6, 2019 /PRNewswire/ --Intermolecular, Inc. (IMI) has signed a definitive agreement pursuant to which a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany, a leading science and technology company, will acquire Intermolecular for $1.20 per share in an all cash transaction, representing an equity value of Intermolecular of approximately $62 million. The acquisition has been unanimously approved by Intermolecular's Board of Directors and the Executive Board of Merck KGaA, Darmstadt, Germany.
SAN JOSE, Calif. , April 24, 2019 /PRNewswire/ -- Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials innovation, will hold a conference call on Tuesday, May 14, 2019 at 5:00 ...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Intermolecular, Inc. (NASDAQ:IMI) shareholders should be happy to see the share price up 14% in the last month. But tha...
Intermolecular Inc (NASDAQ:IMI) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.